You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

Investigational Drug Information for Tesofensine


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Tesofensine?

Tesofensine is an investigational drug.

There have been 13 clinical trials for Tesofensine. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2003.

The most common disease conditions in clinical trials are Obesity, Syndrome, and Prader-Willi Syndrome. The leading clinical trial sponsors are Saniona, NeuroSearch A/S, and Boehringer Ingelheim.

Recent Clinical Trials for Tesofensine
TitleSponsorPhase
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi SyndromeSanionaPhase 2
Phase 2b Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)SanionaPhase 2
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)SanionaPhase 2

See all Tesofensine clinical trials

Clinical Trial Summary for Tesofensine

Top disease conditions for Tesofensine
Top clinical trial sponsors for Tesofensine

See all Tesofensine clinical trials

Development Update and Market Projection for Tesofensine

Introduction

Tesofensine, a monoamine reuptake inhibitor, has been a focal point of interest in the pharmaceutical industry due to its promising results in various clinical trials. Developed by Saniona, a clinical-stage biopharmaceutical company, tesofensine is poised to make a significant impact in the treatment of obesity and other conditions.

Mechanism of Action

Tesofensine works by modulating brain activity by increasing the levels of three key neurotransmitters: dopamine, serotonin, and noradrenaline. These neurotransmitters play crucial roles in regulating appetite, food-seeking behavior, and metabolism, making tesofensine an effective candidate for treating obesity and related disorders[1].

Clinical Trials and Progress

Obesity Treatment

Tesofensine has shown remarkable efficacy in clinical trials for obesity. A Phase 3 study conducted by Saniona's partner, Medix, in Mexico has yielded favorable results. The Mexican food and drug administration, COFEPRIS, has expressed a favorable opinion on tesofensine for the treatment of obesity, paving the way for potential regulatory approval[1].

Parkinson's Disease

In addition to its application in obesity, tesofensine has been explored for its potential in treating Parkinson's Disease (PD). A pilot Phase 2 trial, known as the ADVANS study, demonstrated modest improvements in patients with advanced PD, particularly in activities of daily living and motor function. The study also showed a reduction in "off" time, which is a significant benefit for patients experiencing levodopa-related motor fluctuations[3].

Market Potential

Obesity Market

The obesity market, particularly in Mexico, is growing rapidly. According to Medix’s estimates, the obesity market in Mexico is expected to reach about USD 190 million in 2023, with a growth rate of approximately 16% per year. Tesofensine, with its safety profile, efficacy, and oral administration, is positioned to be a competitive product in this market, especially given the rising demand for effective and safe obesity treatments[1].

Global Market

Globally, tesofensine could have a significant impact due to its potential to produce weight loss twice that of currently approved obesity drugs. This was highlighted in a study published in The Lancet, which suggested that tesofensine should be studied in Phase III trials to further establish its efficacy and safety[2].

Regulatory Pathway

Saniona is making steady progress in the regulatory approval process for tesofensine. In Mexico, the favorable opinion from COFEPRIS’ technical committee is a crucial step towards final approval. Additionally, for the treatment of rare eating disorders such as Hyperphagia-Obesity (HO) and Prader-Willi Syndrome (PWS), the FDA has confirmed that Tesomet (a combination of tesofensine and metoprolol) may be advanced via the 505(b)(2) pathway, which could expedite the approval process[1].

Partnership and Licensing

Saniona is actively seeking partnerships to further develop and commercialize its drug candidates, including tesofensine. The company has existing partnerships with Boehringer Ingelheim, Medix, and Cephagenix, and is aiming to secure additional licensing deals to bring its candidates to market. A successful partnership could significantly enhance the market reach and commercial viability of tesofensine[1][4].

Financial and Development Risks

While tesofensine shows great promise, Saniona faces inherent development risks associated with its pipeline. The majority of its internally developed candidates are in early stages, which carries a high level of risk. However, progress with tesofensine or its combination product, Tesomet, could help balance this risk and provide a more stable development portfolio[4].

Future Outlook

Upcoming Milestones

Saniona is set to continue its clinical development activities, with key milestones including the start of a Phase I MAD/biomarker study with SAN711 and the progression of preclinical work for SAN2355. The ongoing approval process for tesofensine in Mexico is also a critical focus area[5].

Market Impact

Given its efficacy and safety profile, tesofensine is poised to make a significant impact in the obesity treatment market. Its ability to be administered orally and its comparable efficacy to GLP-1 analogs make it a competitive option. As the obesity epidemic continues to grow globally, the demand for effective treatments like tesofensine is expected to rise.

"Tesofensine can produce weight loss twice that of currently approved obesity drugs," - Professor Arne Astrup, Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen[2].

Key Takeaways

  • Clinical Efficacy: Tesofensine has shown significant efficacy in treating obesity and has potential in treating Parkinson's Disease.
  • Market Potential: The drug is poised to capture a substantial share of the growing obesity market, particularly in Mexico.
  • Regulatory Progress: Favorable opinions from regulatory bodies and ongoing approval processes indicate a positive trajectory.
  • Partnerships: Saniona is actively seeking partnerships to enhance the commercial viability of tesofensine.
  • Development Risks: While there are risks associated with early-stage development, progress with tesofensine could mitigate these risks.

FAQs

What is tesofensine and how does it work?

Tesofensine is a monoamine reuptake inhibitor that increases the levels of dopamine, serotonin, and noradrenaline in the brain, helping to regulate appetite and metabolism.

What conditions is tesofensine being developed to treat?

Tesofensine is primarily being developed for the treatment of obesity and is also being explored for its potential in treating Parkinson's Disease and rare eating disorders like Hyperphagia-Obesity (HO) and Prader-Willi Syndrome (PWS).

What is the current regulatory status of tesofensine?

Tesofensine has received a favorable opinion from COFEPRIS in Mexico for the treatment of obesity and is progressing through the regulatory approval process. For HO and PWS, it may be advanced via the 505(b)(2) pathway in the U.S.

How does tesofensine compare to other obesity treatments?

Tesofensine has shown to produce weight loss twice that of currently approved obesity drugs and can be administered orally, making it a competitive option in the market.

What are the key milestones for tesofensine in the near future?

Key milestones include the ongoing approval process in Mexico, potential partnerships, and the progression of other clinical and preclinical studies within Saniona's pipeline.

Sources

  1. Saniona AB (PUBL) Interim Report January – March 2023.
  2. EurekAlert - New promising obesity drug may have huge potential.
  3. JAMA Neurology - Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Advanced Parkinson Disease.
  4. Saniona - Transformational Deal Warrants an Upgrade.
  5. Redeye - Saniona Q2: Continued progress, exciting autumn ahead.
Last updated: 2025-01-02

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.